

# Hereditary angioedema – Pipeline Insight, 2020

<https://marketpublishers.com/r/H5971D8B65EEN.html>

Date: September 2020

Pages: 100

Price: US\$ 2,500.00 (Single User License)

ID: H5971D8B65EEN

## Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Hereditary angioedema – Pipeline Insight, 2020," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Hereditary angioedema pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Hereditary angioedema Understanding

#### Hereditary angioedema: Overview

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger. Episodes involving the intestinal tract cause severe abdominal pain, nausea, and vomiting. Swelling in the airway can restrict breathing and lead to life-threatening obstruction of the airway. About one-third of people with this condition develop a non-itchy rash called erythema marginatum during an attack.

Symptoms of hereditary angioedema typically begin in childhood and worsen during

puberty. On average, untreated individuals have an attack every 1 to 2 weeks, and most episodes last for about 3 to 4 days. The frequency and duration of attacks vary greatly among people with hereditary angioedema, even among people in the same family.

There are three types of hereditary angioedema, called types I, II, and III, which can be distinguished by their underlying causes and levels of a protein called C1 inhibitor in the blood. The different types have similar signs and symptoms. Type III was originally thought to occur only in women, b.

## Symptoms

The symptoms of Hereditary angioedema includes:

Angioedema

Abdominal pain

Ascites

Facial edema

Intestinal edema

## Diagnosis

It is important to note that MOST cases of angioedema or swelling are NOT HAE or C1 Inhibitor Deficiency. Laboratory analysis of blood samples, or genetic samples, are required to establish an HAE diagnosis.

There are three specific blood tests used to confirm Hereditary Angioedema Type I or II.

C1-inhibitor quantitative (antigenic)

C1-inhibitor functional

C4

## Treatment

The medication(s) listed below have been approved by the Food and Drug Administration (FDA) as orphan products for treatment of this condition

C1 esterase inhibitor (human) (Brand name: Cinryze) - Manufactured by ViroPharma Biologics, Inc. was approved June 2018 for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE).

Icatibant (Brand name: Firazyr) - Manufactured by Shire Orphan Therapies is FDA-approved indication for the treatment of acute attacks of hereditary angioedema in adults 18 years of age and older.

Ecallantide (Brand name: Kalbitor) - Manufactured by Dyax Corp is FDA-approved indication for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older

## Hereditary angioedema Emerging Drugs Chapters

This segment of the Hereditary angioedema report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Hereditary angioedema Emerging Drugs

### BCX7353: BioCryst Pharmaceuticals

Berotralstat (BCX7353) is an oral inhibitor of plasma kallikrein in development for the prevention and treatment of hereditary angioedema (HAE). The US Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353). The Prescription Drug User Fee Act (PDUFA) date for the NDA is December 2020.

### KVD900: KalVista Pharmaceuticals

KVD900 is a candidate from our oral portfolio of plasma kallikrein inhibitors. It exhibits high solubility and high permeability and is uniquely suited for on-demand treatment of HAE attacks, with rapid uptake into the plasma and high plasma concentrations. Data in phase II clinical trial for KVD900 is anticipated in the fourth quarter of 2020.

#### PHA121: Pharvaris

PHA121 is a novel small molecule with drug-like properties. In preclinical studies, PHA121 demonstrates highly potent and selective competitive antagonism of the B2 receptor, and shows rapid and potent activity on oral dosing in a bradykinin-mediated disease model. It is currently in phase I stage of development.

#### BMN 331: BioMarin Pharmaceutical

BMN 331 is a gene therapy product candidate for HAE. It is currently in preclinical stage of development.

Further product details are provided in the report

#### Hereditary angioedema: Therapeutic Assessment

This segment of the report provides insights about the different Hereditary angioedema drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Hereditary angioedema

There are approx. 30+ key companies which are developing the therapies for Hereditary angioedema. The companies which have their Hereditary angioedema drug candidates in the most advanced stage, i.e. NDA include BioCryst Pharmaceuticals and others.

#### Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hereditary angioedema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravenous

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Gene therapies

Small molecule

Vaccines

Polymers

Peptides

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

### Hereditary angioedema: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Hereditary angioedema therapeutic drugs key players involved in developing key drugs.

### Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hereditary angioedema drugs.

### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hereditary angioedema R&D. The therapies under development are focused on novel approaches to treat/improve

Hereditary angioedema.

In February 2020, BioCryst Pharmaceuticals announced that the US Food and Drug Administration (FDA) accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.

KVD900 received Fast Track designation from the US FDA, supporting the Company's belief in the high level of unmet need in HAE and providing a potentially expedited path to drug approval.

BioMarin expect to complete preclinical work with BMN 331 in the year 2020 and in anticipation of a possible clinical trial in early 2021.

## Hereditary angioedema Report Insights

Hereditary angioedema Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## Hereditary angioedema Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hereditary angioedema drugs?

How many Hereditary angioedema drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hereditary angioedema?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hereditary angioedema therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hereditary angioedema and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

BioCryst Pharmaceuticals

KalVista Pharmaceuticals

Pharvaris

BioMarin Pharmaceutical

Ionis Pharmaceuticals, Inc.

Pharming Technologies B.V.

Adverum Biotechnologies



Intellia Therapeutics

Pharming Group NV

## Key Products

BCX7353

KVD900

PHA121

BMN 331

IONIS-PKK-LRx

rhC1INH

ADVM 053

Research Programme: hereditary angioedema therapeutics

Conestat alfa

## Contents

Introduction

Executive Summary

Hereditary angioedema: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Hereditary angioedema – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Hereditary angioedema companies' collaborations, Licensing, Acquisition -Deal Value

Trends

Hereditary angioedema Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III and NDA)

Comparative Analysis

BCX7353: BioCryst Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Mid Stage Products (Phase II)

Comparative Analysis

KVD900: KalVista Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

## Early Stage Products (Phase I)

### Comparative Analysis

## PHA121: Pharvaris

### Product Description

### Research and Development

### Product Development Activities

## Drug profiles in the detailed report.....

## Pre-clinical and Discovery Stage Products

### Comparative Analysis

## BMN 331: BioMarin Pharmaceutical

### Product Description

### Research and Development

### Product Development Activities

## Inactive Products

### Comparative Analysis

## Hereditary angioedema Key Companies

## Hereditary angioedema Key Products

## Hereditary angioedema- Unmet Needs

## Hereditary angioedema- Market Drivers and Barriers

## Hereditary angioedema- Future Perspectives and Conclusion

## Hereditary angioedema Analyst Views

## Hereditary angioedema Key Companies

## Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Hereditary angioedema

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Hereditary angioedema

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Hereditary angioedema – Pipeline Insight, 2020

Product link: <https://marketpublishers.com/r/H5971D8B65EEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H5971D8B65EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970